HUS2300037I1 - Piperidinon karboxamid azaindan CGRP receptor antagonisták - Google Patents

Piperidinon karboxamid azaindan CGRP receptor antagonisták

Info

Publication number: HUS2300037I1
Authority: HU; Hungary
Prior art keywords: receptor antagonists; cgrp receptor; piperidinone carboxamide; carboxamide azaindane; piperidinone
Prior art date: 2010-11-12

Application number

HUS2300037C

Other languages

English (en)

Original Assignee

Merck Sharp & Dohme Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-11-12

Filing date

2023-10-25

Publication date

2023-11-28

2023-10-25 Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc

2023-11-28 Publication of HUS2300037I1 publication Critical patent/HUS2300037I1/hu

Links

108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 title 1
102000008323 calcitonin gene-related peptide receptor activity proteins Human genes 0.000 title 1
150000003857 carboxamides Chemical class 0.000 title 1
LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 title 1
XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 title 1
239000002464 receptor antagonist Substances 0.000 title 1
229940044551 receptor antagonist Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems

HUS2300037C 2010-11-12 2023-10-25 Piperidinon karboxamid azaindan CGRP receptor antagonisták HUS2300037I1 (hu)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US41307710P	2010-11-12	2010-11-12
US201061425034P	2010-12-20	2010-12-20
EP11787987.4A EP2638042B1 (en)	2010-11-12	2011-11-10	Piperidinone carboxamide azaindane cgrp receptor antagonists

Publications (1)

Publication Number	Publication Date
HUS2300037I1 true HUS2300037I1 (hu)	2023-11-28

Family

ID=45034191

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HUE14185954A HUE031010T2 (hu)	2010-11-12	2011-11-10	Piperidinon karboxamid azaindan CGRP receptor antagonisták
HUS2300037C HUS2300037I1 (hu)	2010-11-12	2023-10-25	Piperidinon karboxamid azaindan CGRP receptor antagonisták

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
HUE14185954A HUE031010T2 (hu)	2010-11-12	2011-11-10	Piperidinon karboxamid azaindan CGRP receptor antagonisták

Country Status (42)

Country	Link
US (8)	US8912210B2 (hu)
EP (2)	EP2638042B1 (hu)
JP (1)	JP5642883B2 (hu)
KR (1)	KR101537877B1 (hu)
CN (1)	CN103328478B (hu)
AR (1)	AR083831A1 (hu)
AU (1)	AU2011326454B2 (hu)
BR (1)	BR112013011448B8 (hu)
CA (1)	CA2817100C (hu)
CL (1)	CL2013001289A1 (hu)
CO (1)	CO6801723A2 (hu)
CR (1)	CR20130214A (hu)
CY (1)	CY1118362T1 (hu)
DK (2)	DK2821407T3 (hu)
DO (1)	DOP2013000103A (hu)
EA (1)	EA022850B1 (hu)
EC (1)	ECSP13012676A (hu)
ES (2)	ES2525021T3 (hu)
FI (1)	FIC20230034I1 (hu)
FR (1)	FR23C1039I1 (hu)
GT (1)	GT201300122A (hu)
HK (1)	HK1200163A1 (hu)
HR (2)	HRP20141108T1 (hu)
HU (2)	HUE031010T2 (hu)
IL (1)	IL225978A (hu)
LT (1)	LT2821407T (hu)
MA (1)	MA34650B1 (hu)
ME (2)	ME01922B (hu)
MX (1)	MX2013005246A (hu)
MY (1)	MY165113A (hu)
NI (1)	NI201300043A (hu)
NL (1)	NL301248I2 (hu)
NO (1)	NO2023040I1 (hu)
NZ (1)	NZ610468A (hu)
PE (1)	PE20140240A1 (hu)
PL (2)	PL2821407T3 (hu)
PT (2)	PT2821407T (hu)
RS (2)	RS55416B1 (hu)
SG (2)	SG10201509335VA (hu)
SI (2)	SI2638042T1 (hu)
TW (3)	TWI522355B (hu)
WO (1)	WO2012064910A1 (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI522355B (zh) *	2010-11-12	2016-02-21	默沙東藥廠	六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
WO2012129013A1 (en)	2011-03-18	2012-09-27	Merck Sharp & Dohme Corp.	Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
US9487523B2 (en) *	2012-03-14	2016-11-08	Merck Sharp & Dohme Corp.	Process for making CGRP receptor antagonists
US9174989B2 (en) *	2012-05-09	2015-11-03	Merck Sharp & Dohme Corp.	Process for making CGRP receptor antagonists
RU2690006C2 (ru) *	2013-09-16	2019-05-30	Мерк Шарп И Доум Корп.	Композиции антагонистов рецепторов cgrp
AU2015214502B2 (en) *	2014-02-05	2019-06-06	Merck Sharp & Dohme Llc	Tablet formulation for CGRP-active compounds
FR3030521B1 (fr) *	2014-12-23	2019-07-26	Galderma Research & Development	Nouveaux composes heterocycliques et leur utilisation en medecine ainsi qu'en cosmetique
GB201707938D0 (en)	2017-05-17	2017-06-28	Univ Sheffield	Compounds
GB201908430D0 (en) *	2019-06-12	2019-07-24	Heptares Therapeutics Ltd	Cgrp antagonist compounds
CN110787163B (zh) *	2019-12-05	2020-06-02	河北医科大学第二医院	一种用于神经保护和促进神经再生的药物组合物及其制剂
CN112353767A (zh) *	2020-11-16	2021-02-12	海南锦瑞制药有限公司	一种盐酸地尔硫卓和普瑞巴林组合物及其制备方法及其应用
WO2022140537A1 (en)	2020-12-22	2022-06-30	Allergan Pharmaceuticals International Limited	Treatment of migraine
EP4301362A1 (en)	2021-03-02	2024-01-10	CGRP Diagnostics GmbH	Treatment and/or reduction of occurrence of migraine
WO2023026205A1 (en)	2021-08-24	2023-03-02	Cgrp Diagnostics Gmbh	Preventative treatment of migraine
WO2023119327A1 (en) *	2021-12-20	2023-06-29	Msn Laboratories Private Limited, R&D Center	Process for the preparation of a pure amorphous form of ubrogepant
CN117003762A (zh) *	2022-04-29	2023-11-07	熙源安健医药（上海）有限公司	哌啶甲酰胺氮杂茚满类衍生物及其制备方法和用途
WO2024081718A1 (en)	2022-10-11	2024-04-18	Allergan Pharmaceuticals International Limited	Cgrp receptor antagonist for the treatment of migraine

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4166452A (en)	1976-05-03	1979-09-04	Generales Constantine D J Jr	Apparatus for testing human responses to stimuli
US4256108A (en)	1977-04-07	1981-03-17	Alza Corporation	Microporous-semipermeable laminated osmotic system
US4265874A (en)	1980-04-25	1981-05-05	Alza Corporation	Method of delivering drug with aid of effervescent activity generated in environment of use
CA2519515A1 (en)	2003-03-14	2004-10-14	Merck & Co., Inc.	Benodiazepine spirohydantoin cgrp receptor antagonists
ATE535514T1 (de)	2003-03-14	2011-12-15	Merck Sharp & Dohme	Carboxamid-spirohydantoin-cgrp-rezeptor- antagonisten
JO2355B1 (en) *	2003-04-15	2006-12-12	ميرك شارب اند دوم كوربوريشن	Hereditary calcitonin polypeptide receptor antagonists
CN101018781A (zh) *	2004-09-13	2007-08-15	默克公司	双环n－酰苯胺螺内酰胺cgrp受体拮抗剂
US7390798B2 (en)	2004-09-13	2008-06-24	Merck & Co., Inc.	Carboxamide spirolactam CGRP receptor antagonists
EP1861399B1 (en) *	2005-03-14	2011-12-14	Merck Sharp & Dohme Corp.	Cgrp receptor antagonists
EP2024358B1 (en) *	2006-05-09	2014-11-05	Merck Sharp & Dohme Corp.	Substituted spirocyclic cgrp receptor antagonists
AU2008262403B2 (en) *	2007-06-05	2013-11-14	Merck Sharp & Dohme Llc	Carboxamide heterocyclic CGRP receptor antagonists
US20120149698A1 (en) *	2007-11-22	2012-06-14	Boehringer Ingelheim International Gmbh	Nouvel compounds
US8044043B2 (en) *	2008-04-11	2011-10-25	Bristol-Myers Squibb Company	CGRP receptor antagonists
WO2010139717A1 (de) *	2009-06-05	2010-12-09	Boehringer Ingelheim International Gmbh	Neue verbindungen
TWI522355B (zh) *	2010-11-12	2016-02-21	默沙東藥廠	六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
US8883807B2 (en) *	2010-11-12	2014-11-11	Merck Sharp & Dohme Corp.	Piperidinone carboxamide indane CGRP receptor antagonists
EP2654421B1 (en) *	2010-12-22	2016-10-19	Merck Sharp & Dohme Corp.	Fused heterocyclic indane carboxamide as cgrp receptor antagonists
WO2013066360A1 (en) *	2010-12-22	2013-05-10	Merck Sharp & Dohme Corp.	Fused heterocyclic azaindane carboxamide cgrp receptor antagonists
WO2012129013A1 (en) *	2011-03-18	2012-09-27	Merck Sharp & Dohme Corp.	Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
WO2013036861A1 (en) *	2011-09-08	2013-03-14	Codexis, Inc	Biocatalysts and methods for the synthesis of substituted lactams
US9487523B2 (en) *	2012-03-14	2016-11-08	Merck Sharp & Dohme Corp.	Process for making CGRP receptor antagonists
JP6140266B2 (ja) *	2012-03-14	2017-05-31	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	不斉相間移動触媒としてのビス四級シンコナアルカロイド塩
US9174989B2 (en) *	2012-05-09	2015-11-03	Merck Sharp & Dohme Corp.	Process for making CGRP receptor antagonists
US9296750B2 (en) *	2012-05-09	2016-03-29	Merck Sharp & Dohme Corp.	Spirolactam CGRP receptor antagonists
WO2013169574A2 (en) *	2012-05-09	2013-11-14	Merck Sharp & Dohme Corp.	Aliphatic spirolactam cgrp receptor antagonists
WO2013169563A1 (en) *	2012-05-09	2013-11-14	Merck Sharp & Dohme Corp.	Pyridine cgrp receptor antagonists
RU2690006C2 (ru) *	2013-09-16	2019-05-30	Мерк Шарп И Доум Корп.	Композиции антагонистов рецепторов cgrp
AU2015214502B2 (en) *	2014-02-05	2019-06-06	Merck Sharp & Dohme Llc	Tablet formulation for CGRP-active compounds
CA2949480A1 (en) *	2014-02-24	2015-08-27	Urigen Pharmaceuticals, Inc.	Compositions of pentosan polysulfate salts for oral administration and methods of use
US20180092899A1 (en) *	2016-09-30	2018-04-05	Merck Sharp & Dohme Corp.	Method of treating acute migraine with cgrp-active compound

2011
- 2011-11-09 TW TW104104475A patent/TWI522355B/zh active
- 2011-11-09 TW TW104104474A patent/TWI501968B/zh active
- 2011-11-09 TW TW100140962A patent/TWI487706B/zh active
- 2011-11-10 PE PE2013000966A patent/PE20140240A1/es active IP Right Grant
- 2011-11-10 ES ES11787987.4T patent/ES2525021T3/es active Active
- 2011-11-10 US US13/293,177 patent/US8912210B2/en active Active
- 2011-11-10 PL PL14185954T patent/PL2821407T3/pl unknown
- 2011-11-10 EP EP11787987.4A patent/EP2638042B1/en active Active
- 2011-11-10 ME MEP-2014-145A patent/ME01922B/me unknown
- 2011-11-10 PT PT141859546T patent/PT2821407T/pt unknown
- 2011-11-10 AU AU2011326454A patent/AU2011326454B2/en active Active
- 2011-11-10 CN CN201180064736.XA patent/CN103328478B/zh active Active
- 2011-11-10 MX MX2013005246A patent/MX2013005246A/es active IP Right Grant
- 2011-11-10 RS RS20160964A patent/RS55416B1/sr unknown
- 2011-11-10 PL PL11787987T patent/PL2638042T3/pl unknown
- 2011-11-10 SI SI201130327T patent/SI2638042T1/sl unknown
- 2011-11-10 DK DK14185954.6T patent/DK2821407T3/da active
- 2011-11-10 US US13/293,166 patent/US8754096B2/en active Active
- 2011-11-10 WO PCT/US2011/060081 patent/WO2012064910A1/en active Application Filing
- 2011-11-10 NZ NZ610468A patent/NZ610468A/en unknown
- 2011-11-10 MY MYPI2013001607A patent/MY165113A/en unknown
- 2011-11-10 LT LTEP14185954.6T patent/LT2821407T/lt unknown
- 2011-11-10 AR ARP110104204A patent/AR083831A1/es active IP Right Grant
- 2011-11-10 HU HUE14185954A patent/HUE031010T2/hu unknown
- 2011-11-10 DK DK11787987.4T patent/DK2638042T3/en active
- 2011-11-10 EP EP14185954.6A patent/EP2821407B1/en active Active
- 2011-11-10 RS RS20140621A patent/RS53610B1/en unknown
- 2011-11-10 CA CA2817100A patent/CA2817100C/en active Active
- 2011-11-10 SI SI201131014A patent/SI2821407T1/sl unknown
- 2011-11-10 SG SG10201509335VA patent/SG10201509335VA/en unknown
- 2011-11-10 EA EA201390683A patent/EA022850B1/ru not_active IP Right Cessation
- 2011-11-10 US US13/293,186 patent/US8481556B2/en active Active
- 2011-11-10 PT PT117879874T patent/PT2638042E/pt unknown
- 2011-11-10 BR BR112013011448A patent/BR112013011448B8/pt active IP Right Grant
- 2011-11-10 ES ES14185954.6T patent/ES2604827T3/es active Active
- 2011-11-10 SG SG2013034145A patent/SG190137A1/en unknown
- 2011-11-10 KR KR1020137014960A patent/KR101537877B1/ko active IP Right Grant
- 2011-11-10 JP JP2013538871A patent/JP5642883B2/ja active Active
- 2011-11-10 ME MEP-2016-257A patent/ME02552B/me unknown
2013
- 2013-04-25 IL IL225978A patent/IL225978A/en active IP Right Grant
- 2013-05-06 MA MA35880A patent/MA34650B1/fr unknown
- 2013-05-09 DO DO2013000103A patent/DOP2013000103A/es unknown
- 2013-05-09 CL CL2013001289A patent/CL2013001289A1/es unknown
- 2013-05-10 CR CR20130214A patent/CR20130214A/es unknown
- 2013-05-10 NI NI201300043A patent/NI201300043A/es unknown
- 2013-05-10 GT GT201300122A patent/GT201300122A/es unknown
- 2013-05-30 CO CO13133033A patent/CO6801723A2/es active IP Right Grant
- 2013-06-12 EC ECSP13012676 patent/ECSP13012676A/es unknown
2014
- 2014-09-12 US US14/485,259 patent/US9499545B2/en active Active
- 2014-11-14 HR HRP20141108AT patent/HRP20141108T1/hr unknown
2015
- 2015-01-15 HK HK15100502.4A patent/HK1200163A1/zh unknown
2016
- 2016-10-14 US US15/293,569 patent/US9833448B2/en active Active
- 2016-12-05 HR HRP20161641TT patent/HRP20161641T1/hr unknown
- 2016-12-06 CY CY20161101255T patent/CY1118362T1/el unknown
2017
- 2017-12-04 US US15/830,131 patent/US10272077B2/en active Active
2019
- 2019-04-26 US US16/396,056 patent/US20190275024A1/en not_active Abandoned
2020
- 2020-07-28 US US16/940,943 patent/US20210008055A1/en not_active Abandoned
2023
- 2023-10-20 NO NO2023040C patent/NO2023040I1/no unknown
- 2023-10-25 HU HUS2300037C patent/HUS2300037I1/hu unknown
- 2023-10-31 NL NL301248C patent/NL301248I2/nl unknown
- 2023-10-31 FR FR23C1039C patent/FR23C1039I1/fr active Active
- 2023-11-10 FI FIC20230034C patent/FIC20230034I1/fi unknown

Also Published As

Publication number	Publication date
SI2638042T1 (sl)	2015-01-30
CN103328478B (zh)	2015-10-07
SG190137A1 (en)	2013-07-31
EA022850B1 (ru)	2016-03-31
IL225978A (en)	2015-11-30
KR101537877B1 (ko)	2015-07-17
FR23C1039I1 (fr)	2023-12-08
NZ610468A (en)	2015-06-26
DOP2013000103A (es)	2013-10-15
US20120122900A1 (en)	2012-05-17
MY165113A (en)	2018-02-28
PT2638042E (pt)	2014-12-09
ES2604827T3 (es)	2017-03-09
MX2013005246A (es)	2013-05-28
NI201300043A (es)	2013-07-01
GT201300122A (es)	2015-06-02
NO2023040I1 (no)	2023-10-20
KR20130087037A (ko)	2013-08-05
JP5642883B2 (ja)	2014-12-17
SI2821407T1 (sl)	2016-12-30
EA201390683A1 (ru)	2013-09-30
TWI501968B (zh)	2015-10-01
TWI487706B (zh)	2015-06-11
HUE031010T2 (hu)	2017-06-28
US20180092900A1 (en)	2018-04-05
BR112013011448B1 (pt)	2021-06-01
CN103328478A (zh)	2013-09-25
EP2638042A1 (en)	2013-09-18
CO6801723A2 (es)	2013-11-29
TW201520214A (zh)	2015-06-01
PL2821407T3 (pl)	2017-04-28
JP2013542260A (ja)	2013-11-21
US8754096B2 (en)	2014-06-17
AU2011326454A1 (en)	2013-05-23
IL225978A0 (en)	2013-06-27
EP2638042B1 (en)	2014-09-24
CR20130214A (es)	2013-06-28
US20190275024A1 (en)	2019-09-12
SG10201509335VA (en)	2015-12-30
EP2821407B1 (en)	2016-09-21
ECSP13012676A (es)	2013-08-30
ME01922B (me)	2015-05-20
RS55416B1 (sr)	2017-04-28
AU2011326454B2 (en)	2015-05-21
AR083831A1 (es)	2013-03-27
PT2821407T (pt)	2016-12-06
BR112013011448B8 (pt)	2022-03-29
TW201305165A (zh)	2013-02-01
US9833448B2 (en)	2017-12-05
BR112013011448A2 (pt)	2016-08-09
PE20140240A1 (es)	2014-03-14
TW201520213A (zh)	2015-06-01
ES2525021T3 (es)	2014-12-16
HRP20141108T1 (hr)	2015-01-16
US20210008055A1 (en)	2021-01-14
US20120122899A1 (en)	2012-05-17
DK2638042T3 (en)	2015-01-05
HK1200163A1 (zh)	2015-07-31
CY1118362T1 (el)	2017-06-28
MA34650B1 (fr)	2013-11-02
CA2817100C (en)	2015-09-29
NL301248I2 (nl)	2023-11-20
US8481556B2 (en)	2013-07-09
LT2821407T (lt)	2016-12-12
CL2013001289A1 (es)	2013-08-09
US9499545B2 (en)	2016-11-22
US10272077B2 (en)	2019-04-30
DK2821407T3 (da)	2017-01-02
CA2817100A1 (en)	2012-05-18
HRP20161641T1 (hr)	2017-01-13
US20150005330A1 (en)	2015-01-01
WO2012064910A1 (en)	2012-05-18
PL2638042T3 (pl)	2015-03-31
TWI522355B (zh)	2016-02-21
US20120122911A1 (en)	2012-05-17
RS53610B1 (en)	2015-04-30
ME02552B (me)	2017-02-20
EP2821407A1 (en)	2015-01-07
US20170027925A1 (en)	2017-02-02
FIC20230034I1 (fi)	2023-11-10
US8912210B2 (en)	2014-12-16

Publication	Publication Date	Title
HUS2300037I1 (hu)	2023-11-28	Piperidinon karboxamid azaindan CGRP receptor antagonisták
HUS2200033I1 (hu)	2022-08-28	CGRP receptor antagonisták
PL2927224T3 (pl)	2019-03-29	Antagoniści receptora
EP2637656A4 (en)	2014-04-23	PIPERIDINONE CARBOXAMIDE INDANES, CGRP RECEPTOR ANTAGONISTS
EP2619204A4 (en)	2014-08-27	TRIAZOLOPYRAZINONES AS ANTAGONISTS OF P2X7 RECEPTORS
EP2438041A4 (en)	2012-11-21	PYRAZINE-carboxamide-orexin receptor Antagonist
HK1174914A1 (zh)	2013-06-21	受體拮抗劑
EP2685826A4 (en)	2014-09-03	PIPERIDINONE CARBOXAMIDE SPIROHYDANTOIN, CGRP RECEPTOR ANTAGONISTS
EP2654423A4 (en)	2014-05-28	AZAINDANE ANTAGONISTS HETEROCYCLIC CARBOXAMIDES MERGED FROM CGRP RECEPTORS
EP2771346A4 (en)	2015-06-03	OXINOLINE RECEPTOR ANTAGONISTS OF THE ISOXAZOLOPYRIDINE TYPE
EP2846801A4 (en)	2015-09-30	CGRP RECEPTOR ANTAGONISTS BASED ON PYRIDINE
EP2654421A4 (en)	2014-06-18	CONDENSED HETEROCYCLIC INDAN CARBOXAMIDE CGRP RECEPTOR ANTAGONISTS
IL241743A0 (en)	2015-11-30	Non-competitive nicotinic receptor antagonists
EP2539706A4 (en)	2013-07-31	ARYLPIPERAZONE ANTAGONISTS OF OPIOID RECEPTORS
EP2686324A4 (en)	2014-11-19	Piperidinecarboxamide spirohydantoin-CGRP receptor antagonists
EP2408304A4 (en)	2012-12-12	CGRP RECEPTOR ANTAGONISTS
EP2846800A4 (en)	2015-11-11	HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS
HK1183862A1 (en)	2014-01-10	Piperidinone carboxamide azaindane cgrp receptor antagonists (azaindane)(cgrp)
GB0922455D0 (en)	2010-02-03	Ep2 receptor antagonists